Corvus Pharmaceuticals (CRVS) Interest Expenses (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Interest Expenses of $924000.0 for Q1 2026, up 63.25% year-over-year from $566000.0 in Q1 2025, and up 4763.16% quarter-over-quarter from $19000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Interest Expenses (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Interest Expenses history runs 12 years deep, the most recent figure standing at $924000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 63.25% year-over-year to $924000.0; the TTM figure through Mar 2026 stood at $924000.0 (up 63.25% YoY), while the FY2025 annual figure was $102.1 million, up 12.78% from the prior year.
- Interest Expenses for Q1 2026 stood at $924000.0, up from $19000.0 in the prior quarter.
- The five-year high for Interest Expenses was $1.1 million in Q1 2024, with the low at -$1.3 million in Q4 2024.
- The 5-year median for Interest Expenses is $459000.0 (2023), against an average of $394058.8.
- Peak annual rise in Interest Expenses reached 134.2% in 2024, while the deepest fall reached 374.62% in 2024.
- Corvus Pharmaceuticals' Interest Expenses stood at $430000.0 in 2022, then gained by 7.21% to $461000.0 in 2023, then slumped by 374.62% to -$1.3 million in 2024, then soared by 101.5% to $19000.0 in 2025, then jumped by 4763.16% to $924000.0 in 2026.
- Business Quant data shows CRVS's Interest Expenses at $924000.0 in Q1 2026, $19000.0 in Q4 2025, and $566000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 796,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 796,000.00 |
| Jun 30, 2026 | 796,000.00 |
| Mar 31, 2026 | 924,000.00 |
| Mar 31, 2026 | 924,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 566,000.00 |
| Sep 30, 2025 | 566,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 566,000.00 |
| Mar 31, 2025 | 566,000.00 |
| Dec 31, 2024 | -1.27 Mn |
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | 358,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |